Drug intelligence / Profile preview

T-SN38 C

Development stage: Preclinical
Lead developer: Sichuan University
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**T-SN38 C** is an experimental HER2-targeted antibody-drug conjugate composed of trastuzumab covalently linked to the topoisomerase I inhibitor SN-38. It was designed with a water-soluble polyethylene glycol and carbonate linker system to improve SN-38 solubility while enabling intracellular payload release. In preclinical SKOV-3 HER2-positive ovarian cancer models, T-SN38 C had a drug-to-antibody ratio of approximately 3.4 and showed nanomolar cytotoxicity, with an IC50 of 5.1 ± 0.4 nM after 72 hours. It has not been assigned an INN or reported as a marketed product.

Other names: T-SN38 CT-SN-38 CT-SN 38 C

Targets

TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on T-SN38 C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-SN38 C.

Explore the full profile